Endocyte, Inc.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Sep 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 24, 2027The maintenance fee for Method of imaging with a chelating agent (US 10,420,850) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Folate receptor binding conjugates of antifolates (US 9,192,682) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Conjugates for treating diseases (US 10,624,972) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Nov 5 US 7,875,612 Folate Mimetics and Folate-Receptor Binding Conjugates Thereof · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,546,425 | Folate receptor binding conjugates of antifolates In force (reinstated) · USPTO record | In force (reinstated) | USPTO record | |
| US 9,192,682 | Folate receptor binding conjugates of antifolates In force · USPTO record | In force | USPTO record | |
| US 9,549,992 | Folate Receptor Binding Conjugates of Antifolates In force · Medium confidence | In force | Medium confidence | |
| US 11,219,622 | Folate Receptor Binding Conjugates of Antifolates In force · Medium confidence | In force | Medium confidence | |
| US 9,636,413 | Conjugates for Treating Diseases Caused by Psma Expressing Cells In force · High confidence | In force | High confidence | |
| US 9,782,493 | Conjugates for Treating Diseases Caused by Psma Expressing Cells In force · High confidence | In force | High confidence | |
| US 10,912,840 | Conjugates for Treating Diseases Caused by Psma Expressing Cells In force · High confidence | In force | High confidence | |
| US 10,624,972 | Conjugates for treating diseases In force · USPTO record | In force | USPTO record | |
| US 12,178,892 | Compounds for Positron Emission Tomography In force · High confidence | In force | High confidence | |
| US 10,188,759 | Conjugates for imaging In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 14: 6 patents in force now held by others · 33 lapsed for an unpaid fee · 8 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 18 abandoned · 45 no status recorded
Showing 1 to 10 of 74, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/067,642 | Methods of Use for Car T Cells | Feb 28, 2025 | Pending |
| 18/999,436 | Methods of Treating Cancer | Dec 23, 2024 | Pending |
| 18/963,158 | Sequencing Method for Car T Cell Therapy | Nov 27, 2024 | Pending |
| 18/914,891 | Methods and Compositions for Car T Cell Therapy | Oct 14, 2024 | Pending |
| 18/913,734 | Compounds for Positron Emission Tomography | Oct 11, 2024 | Pending |
| 18/906,001 | Conjugates for Treating Diseases Caused by Psma Expressing Cells | Oct 3, 2024 | Pending |
| 18/823,426 | Methods of Treating Cancer by Targeting Tumor-Associated Macrophages | Sep 3, 2024 | Pending |
| 18/494,613 | Compositions and Methods for Car T Cell Therapy | Oct 25, 2023 | Pending |
| 17/737,471 | Conjugates for Treating Diseases Caused by Psma Expressing Cells | May 5, 2022 | Abandoned |
| 17/524,211 | Methods of Treating Cancer by Targeting Tumor-Associated Macrophages | Nov 11, 2021 | Abandoned |
10 of 74 applications shown.
Pro members see all 74 published applications.